Our previous studies demonstrated that traumatic brain injury (TBI) and ventricular administration of thrombin caused hippocampal neuron loss and cognitive dysfunction via activation of Src family kinases (SFKs). Based on SFK localization in brain, we hypothesized SFK subtypes Fyn and c-Src, as well as SFK downstream molecule Rho-associated protein kinase (ROCK), contribute to cell death and cognitive dysfunction after TBI. We administered nanoparticle wrapped small interfering RNA (siRNA)-Fyn and siRNA-c-Src, or ROCK inhibitor Y-27632 to adult rats subjected to moderate lateral fluid percussion (LFP)–induced TBI. Spatial memory function was assessed from 12 to 16 days, and NeuN stained hippocampal neurons were assessed 16 days after TBI. The combination of siRNA-Fyn and siRNA-c-Src, but neither alone, prevented hippocampal neuron loss and spatial memory deficits after TBI. The ROCK inhibitor Y-27632 also prevented hippocampal neuronal loss and spatial memory deficits after TBI. The data suggest that the combined actions of three kinases (Fyn, c-Src, ROCK) mediate hippocampal neuronal cell death and spatial memory deficits produced by LFP-TBI, and that inhibiting this pathway prevents the TBI-induced cell death and memory deficits.
Get full access to this article
View all access options for this article.
References
1.
PrinsM., GrecoT., AlexanderD., and GizaC.C. (2013). The pathophysiology of traumatic brain injury at a glance. Dis. Model Mech. 6, 1307–1315.
2.
NamjoshiD.R., GoodC., ChengW.H., PanenkaW., RichardsD., CriptonP.A., and WellingtonC.L. (2013). Towards clinical management of traumatic brain injury: a review of models and mechanisms from a biomechanical perspective. Dis. Model Mech. 6, 1325–1338.
3.
GaetzM. (2004). The neurophysiology of brain injury. Clin. Neurophysiol. 115, 4–18.
4.
PerelP., RobertsI., BouamraO., WoodfordM., MooneyJ., and LeckyF. (2009). Intracranial bleeding in patients with traumatic brain injury: a prognostic study. BMC Emerg. Med. 9, 15.
5.
NINDS. (2013). Traumatic Brain Injury: Hope Through Research. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Traumatic-Brain-Injury-Hope-Through
6.
RayS.K., DixonC.E., and BanikN.L. (2002). Molecular mechanisms in the pathogenesis of traumatic brain injury. Histol. Histopathol. 17, 1137–1152.
7.
LiuD., SharpF.R., VanK.C., AnderB.P., GhiasvandR., ZhanX., StamovaB., JicklingG.C., and LyethB.G. (2014). Inhibition of Src family kinases protects hippocampal neurons and improves cognitive function after traumatic brain injury. J. Neurotrauma, 31, 1268–1276.
8.
LiuD.Z., WaldauB., AnderB.P., ZhanX., StamovaB., JicklingG.C., LyethB.G., and SharpF.R. (2016). Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin. J. Cereb. Blood Flow Metab. 37, 2359–2367.
9.
OdaH., KumarS., and HowleyP.M. (1999). Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 96, 9557–9562.
10.
TatosyanA.G., and MizeninaO.A. (2000). Kinases of the Src family: structure and functions. Biochemistry (Mosc.) 65, 49–58.
11.
AuA.K., AnejaR.K., BellM.J., BayirH., FeldmanK., AdelsonP.D., FinkE.L., KochanekP.M., and ClarkR.S. (2012). Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury. J. Neurotrauma, 29, 2013–2021.
12.
OkumaY., LiuK., WakeH., ZhangJ., MaruoT., DateI., YoshinoT., OhtsukaA., OtaniN., TomuraS., ShimaK., YamamotoY., YamamotoH., TakahashiH.K., MoriS., and NishiboriM. (2012). Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann. Neurol. 72, 373–384.
13.
IbrahimZ.A., ArmourC.L., PhippsS., and SukkarM.B. (2013). RAGE and TLRs: relatives, friends or neighbours?. Mol. Immunol. 56, 739–744.
14.
ParsonsS.J., and ParsonsJ.T. (2004). Src family kinases, key regulators of signal transduction. Oncogene, 23, 7906–7909.
15.
UmemoriH., WanakaA., KatoH., TakeuchiM., TohyamaM., and YamamotoT. (1992). Specific expressions of Fyn and Lyn, lymphocyte antigen receptor-associated tyrosine kinases, in the central nervous system. Brain Res. Mol. Brain Res. 16, 303–310.
16.
RossC.A., WrightG.E., ReshM.D., PearsonR.C., and SnyderS.H. (1988). Brain-specific src oncogene mRNA mapped in rat brain by in situ hybridization. Proc. Natl. Acad. Sci. U. S. A. 85, 9831–9835.
17.
SteinP.L., VogelH., and SorianoP. (1994). Combined deficiencies of Src, Fyn, and Yes tyrosine kinases in mutant mice. Genes Dev. 8, 1999–2007.
18.
ThomasS.M., SorianoP., and ImamotoA. (1995). Specific and redundant roles of Src and Fyn in organizing the cytoskeleton. Nature, 376, 267–271.
DubreuilC.I., MarklundN., DeschampsK., McIntoshT.K., and McKerracherL. (2006). Activation of Rho after traumatic brain injury and seizure in rats. Exp. Neurol. 198, 361–369.
21.
JeonB.T., JeongE.A., ParkS.Y., SonH., ShinH.J., LeeD.H., KimH.J., KangS.S., ChoG.J., ChoiW.S., and RohG.S. (2013). The Rho-kinase (ROCK) inhibitor Y-27632 protects against excitotoxicity-induced neuronal death in vivo and in vitro. Neurotox Res. 23, 238–248.
22.
LiuD.Z., ChengX.Y., AnderB.P., XuH., DavisR.R., GreggJ.P., and SharpF.R. (2008). Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons. Neurobiol. Dis. 30, 201–211.
23.
LiuD.Z., and SharpF.R. (2011). The dual role of SRC kinases in intracerebral hemorrhage. Acta Neurochir. Suppl, 111, 77–81.
24.
ArdizzoneT.D., LuA., WagnerK.R., TangY., RanR., and SharpF.R. (2004). Glutamate receptor blockade attenuates glucose hypermetabolism in perihematomal brain after experimental intracerebral hemorrhage in rat. Stroke, 35, 2587–2591
25.
CopaniA., and NicolettiF. Cell-cycle mechanisms and neuronal cell death. (Kluwer Academic/Plenum, 2005).
26.
RodriguezP.L., SahayS., OlabisiO.O., and WhiteheadI.P. (2007). ROCK I-mediated activation of NF-kappaB by RhoB. Cell Signal, 19, 2361–2369.
27.
LiuD.Z., AnderB.P., XuH., ShenY., KaurP., DengW., and SharpF.R. (2010). Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. Ann. Neurol. 67, 526–533.
28.
LiuD.Z., and AnderB.P. (2012). Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal, 2012, 491737.
29.
LiuD.Z., and AnderB.P. (2011). Cell cycle phase transitions: signposts for aberrant cell cycle reentry in dying mature neurons. J. Cytol. Histol. 2, e101.
30.
LiuD.Z., AnderB.P., and SharpF.R. (2010). Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases. Neurobiol. Dis. 37, 549–557.
31.
WuX., WalkerC.L., LuQ., WuW., EddelmanD.B., ParishJ.M., and XuX.M. (2016). RhoA/Rho kinase mediates neuronal death through regulating cPLA2 activation. Mol. Neurobiol. 54, 6885–6895.
32.
LeeL.L., GaloE., LyethB.G., MuizelaarJ.P., and BermanR.F. (2004). Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp. Neurol. 190, 70–78.
33.
De SilvaT.M., KinzenbawD.A., ModrickM.L., ReinhardtL.D., and FaraciF.M. (2016). Heterogeneous impact of ROCK2 on carotid and cerebrovascular function. Hypertension, 68, 809–817.
34.
SummyJ.M., and GallickG.E. (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22, 337–358.
35.
MatsuokaT., and YashiroM. (2014). Rho/ROCK signaling in motility and metastasis of gastric cancer. World J. Gastroenterol. 20, 13756–13766.
PutzkeA.P., VenturaA.P., BaileyA.M., AktureC., Opoku-AnsahJ., CeliktasM., HwangM.S., DarlingD.S., ColemanI.M., NelsonP.S., NguyenH.M., CoreyE., TewariM., MorrisseyC., VessellaR.L., and KnudsenB.S. (2011). Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am. J. Pathol. 179, 400–410.
38.
WuZ., ChangP.C., YangJ.C., ChuC.Y., WangL.Y., ChenN.T., MaA.H., DesaiS.J., LoS.H., EvansC.P., LamK.S., and KungH.J. (2010). Autophagy blockade sensitizes prostate cancer cells towards Src family kinase Inhibitors. Genes Cancer, 1, 40–49.
39.
NamJ.S., InoY., SakamotoM., and HirohashiS. (2002). Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 8, 2430–2436.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
